Helping you become a father
Improvement in sperm DNA integrity with oral antioxidant therapy in patients with high DNA damage
Sergey I. Moskovtsev1*, Keith Jarvi2, Kirk C. Lo2, Kenneth I. Cadesky3, John White1, Leia Spencer2, and J. Brendan M. Mullen1. 1Andrology Laboratory, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital; 2Division of Urology, Department of Surgery, Mount Sinai Hospital, 3LifeQuest Centre for Reproductive Medicine, Toronto, Ontario, Canada.
Note: Fertile One® is the predecessor product to the Coast Science® Male Fertility Supplement. MFSg5 represents an improvement over Fertile One®.
Formulated To Improve Sperm Count
Sperm count refers to the total amount of spermatozoa in the ejaculate. While not the only critical parameter relative to male fertility, higher numbers bode well for conception. The average sperm count today is between 20 and 40 million per milliliter in the Western world. L-methionine, a key ingredient in Coast Science® MFSg5, has been shown to increase sperm count.
Formulated To Improve Sperm Motility
Sperm motility is the ability of sperm to move properly towards an egg. Sperm which do not properly "swim", will not reach the egg in order to fertilize it. Several MFSg5 components positively impact motility: L-methionine, Glutathione, and KSM-66. Vitamin A improves pregnancy rates in male patients with reduced motility in combination therapy with other antioxidants found in MFSg5.
Formulated To Improve Sperm Morphology
Sperm morphology is a way of describing the shape of sperm as observed under a microscope. There is quite a variation in sperm shape, and a sperm sample is considered normal if at least 4% of the sperm observed have "normal" morphology. Morphology is a predictor of success in fertilizing oocytes during in vitro fertilization. The Glutathione in MFSg5 promotes normal sperm morphology.
Formulated To Promote Overall Sperm Integrity and Reduce DNA Fragmentation
Damage to DNA in sperm is an indicator for reduced fertility potential and is more common in men over the age of 45. Glutathione decreases DNA fragmentation, and the Lycopene in Coast Science® MFSg5 protects against lipid and DNA oxidation.
COAST SCIENCE® REPRODUCTIVE COST COMPARISON
This comparison uses standard size bottles of vitamins from the shelf of each retailer. The quantity of each vitamin needed is one or more per day, amounting to 13 separate components of one or more pills per day! Coast Science® MFSg5 contains all of the components in only 4 capsules per day, plus we guarantee the quality, purity and grade of our product.
- Supplement Facts
- Additional Information
Dosage: 4 capsules daily. For best results, take two capsules two times a day, after meals. Drink 6 to 8 glasses of water per day.
Precaution: If a reaction occurs, consult your physician. Do not purchase this product if seal is missing or broken. Do not use with nitroglycerine or any form of prescription nitrate.
Consult your doctor: This product is a dietary supplement, not a medication.
Warning: Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
Refrigerate after opening.
|Dimensions||2.6 × 2.6 × 5.23 in|
- Effects of antioxidant treatment on DNA fragmentation index
- Supporting Components
- Supporting MFS-Fertile One
E. Sagayan, B. Acacio, C. Coulam, G. Sher, M. Nouriani. Kern County Medical
Center, University of California Los Angeles, Bakersfield, CA; Sher
Institute for Reproductive Medicine, Glendale, CA; Sher Institute for Reproductive
Medicine, Los Angeles, CA. (2004, October) Presented at the annual American Society for Reproductive Medicine in Philadelphia, PA.
Conclusion: Treatment of men with DFI > 30% with a 30 to 90 day course of AOT
(Fertile One™) was associated with a statistically significant decrease in the DFI. Extending the treatment beyond 90 days appeared to have no additional benefits of DFI.
Costa M, et al. L-carnitine in ideopathic asthenospermia: a multicenter study. Andrologia 1994;26:155-9.
Czeizel AE. Periconceptual folic acid containing multivitamin supplementation. Eur J Obstet Gynecol ReprodBiol 1998;78(2):151-61.
Dawson EB, et al. Effect of ascorbic acid supplementation on the sperm quality of smokers. Fertil & Steril 1992;58(5):1034-9.
Geva E, et al. The effect of antioxidant treatment on human spermatazoa and fertilization rate in an in vitrofertilization program. Fertil & Steril 1996;66(3):430-4
Kessopoulou E, et al. A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin
E to treat reactive oxygen species associated with male infertility. Fertil & Steril 1995;64(4):825-31
Scott R, et al. The effect or oral selenium supplementation on human sperm motility. Br J Urol 1998;82:76-80.
Takihara H, et al. Zinc sulphate therapy for infertile male with or without varicocelectomy. Urol 1987;29(6):638-41.
Salvati G, Genovesi G, Marcellini L, et al. Effects of Panax ginseng C.A. Meyer saponins on male fertility. Panmineva Med 1996;38:249-54.
Zheng R-L and Zhang H. Effect of ferulic acid on fertile and asthenozoospermic infertile human sperm motility, viability, lipid peroxidation, and cyclic nucleotides. Free Rad Biol & Med 1997;22(4):581-6.
Abell A, Ernst E, Bonde JP. High sperm density among members of organic farmer’s association. Lancet 1994;343: 1498.
Hruska KS, Furth PA, Seifer DB, et al. Enviornmental factors in infertility. Clin Obstet Gynecol 2000;43:821-9.
Zhang JP, Meng QY, Wang Q, et al. Effect of smoking on semen quality of infertile men in Shandong, China. Asian J Androl 2000;2: 143-6.
Fraga CG, Motchnik PA, Shigenage MK, et al. Ascorbic acid protects against endogenous oxidative DNA damage in human sperm. Proc Nati Acad Sci 1991;88:11003-6.
Dawson EB, Harris WA, Teter MC, Powell LC. Effect of ascorbic acid supplementation on the sperm quality of smokers. Fertile Steril 1992;58:1034-9
Dawson EB, Harris WA, McGanity WJ. Effect of ascorbic acid on sperm fertility. Fed Proc 1983;42:531 [abstr 31403].
Dawson EB, Harris WA, Powell LC. Relationship between ascorbic acid and male fertility. In: Aspects of Some Vitamins, Minerals and Enzymes in Health and Disease, ed. GH Bourne. World Rev Nutr Diet 1990;62:1-26[review].
Dawson EB, Harris WA, Rankin WE, et al. Effect of ascorbic acid on male fertility. Ann N Y Acad Sci 1987;498:312-23.
Rolf C, Cooper TG, Yeung CH, Nieschlag E. Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Hum Reprod 1999;14:1028-33.
Prasad AS, Cossack ZT. Zinc supplementation and growth in sickle cell disease. Ann Intern Med 1984;100:367-71.
Kvist U, Kjellberg S, Bjorndahl L, et al. Seminal fluid from men with agenesis of the Wolffian ducts: zinc-binding properties and effects on sperm chromatin stability. Int J Androl 1990;13:245-52.
Saaranen M, Suistomaa U, Kantola M, et al. Lead magnesium, selenium and zinc in human seminal fluid: comparison with semen parameters and fertility. Hum Reprod 1987;2:475-9.
Danscher G, Hammen R, Fjerdingstad E, Rebbe H. Zinc content of human ejaculate and motility of sperm cells. Int J Androl 1978;1:576-81.
Carpino A, Siciliano L, Petroni MF, et al. Low seminal zinc bound to high molecular weight proteins in asthenozoospermic patients: evidence of increased sperm zinc content in oligoasthenozoospermic patients. Hum Reprod 1998;13:111-4.
Stankovic H, Mikac-Devic D. Zinc and copper in human semen. Clin Chim Acta 1976;70:123-6.
Hartoma TR, Nahoul K, Netter A. Zinc, plasma androgens and male sterility. Lancet 1977;2:1125-6.
Wong et al., 2002 Fertile and Sterility 2002;77:491-8.
Stankovic H, Mikac-Devic D. Zinc and copper in human semen. Clin Chim Acta 1976;70:123-6.
Kynaston HG, Lewis-Jones DI, Lynch RV, Desmond AD. Changes in seminal quality following oral zinc therapy. Andrologia 1988;20:21-2.
Tikkiwal M, Ajmera RL, Mathur NK. Effect on zinc administration on seminal zinc and fertility of oligospermic males. Indian J Physiol Pharmacol 1987;31:30-4.
Marmar JL, Katz S, Praiss DE, DeBenedictis TJ. Semen zinc levels in infertile and postvasectomy patients and patients with prostatitis. Fertil Steril 1975;26:1057-63.
Omu AE, Dashti H, Al-Othman S. Treatment of asthenozoospermia with zinc sulphate:andrological, immunological and obstetric outcome. Eur J Obstet Gynecol Reprod Biol 1998;79:179-84.
Scott R, MacPherson A, Yates RWS, et al. The effect of oral selenium supplementation on human sperm motility. Br J Urol 1998;82:76-80.
Sandler B, Faragher B. Treatment of oligospermia with vitamin B12. Infertility 1984;7:133-8.
Kumamoto Y, Maruta H, Ishigami J, et al. Clinical efficacy of mecobalamin in treatment of oligozoospermia. Acta Urol Jpn 1988;34:1109-32.
Costa M, Canale D, Filicori M, et al. L-carnitine in idiopathic asthenozoospermia: a multicenter study. Andrologia 1994;26:155-9.
Vitali G, Parente R, Melotti C. Carnitine supplementation in human idiopathic asthenospermia: clinical results. Drugs Exp Clin Res 1995;21:157-9.
Lewin A, Lavon H. The effect on coenzyme Q10 on sperm motility and function. Mol Aspects Med 1997;18 Suppl:S213-9.
Thiessen DD, Ondrusek G, Coleman RV. Vitamin E and sex behavior in mice. Nutr Metab 1975;18:116-9.
Bayer R. Treatment of infertility with vitamin E. Int J Fertil 1960;5:70-8.
Clinical Studies Supporting MFS-Fertile One
Geva E, Bartoov B, Zabludovsky N, et al. The effect of antioxidant treatment on human spermatozoa and fertilization rate in an in vitro fertilization program. Fertil Steril 1996;66:430-4.
Martin-Du Pan RC, Sakkas D. Is antioxidant therapy a promising strategy to improve human reproduction? Are anti-oxidants useful in the treatment of male infertility? Hum Reprod 1998;13:2984-5.
Salvati G, Genovesi G, Marcellini L, et al. Effects of Panaz ginseng C.A. Meyer saponins on male fertility. Panmineva Med 1996;38:249-54.
Aquino R, De Feo V, De Simone F, et al. Plant metabolites, new compounds and antiinflammatory activity of Uncaria tomentosa. J Nat Prod 1991;54:453-9.
Rizzi R, Re F, Bianchi A, et al. Mutagenic and antimutagentic activities of Uncaria tomentosa and its extracts. J Ethnopharmacol 1993;38:63-77.